1- ESC 2019 | New European Guidelines on “Chronic Coronary Syndromes”
In Paris, during the European Society of Cardiology (ESC) Congress 2019 Scientific Sessions, new guidelines for the diagnosis and treatment of chronic coronary syndromes were presented. This document, simultaneously published in Euro Heart J, updates the 2013 guidelines on stable ischemic heart disease and takes out the word “stable” so as to emphasize that the disease is anything but that.
Read more HERE
2- Experts Reach Consensus on Post TAVR Pacemaker Indication
This new consensus published this week in J Am Coll Cardiol has provided us with an algorithm to manage conduction disturbances after transcatheter aortic valve replacement. This consensus is intended to reduce potential deaths caused by conduction disturbances and, at the same time, reduce unnecessary definite pacemaker implantation.
Read more HERE
3- ESC 2019 | DAPA-HF: Dapagliflozin Shows Benefit for All Subgroups
Dapagliflozin (a sodium glucose co-transporter 2 [SGLT2] inhibitor), when indicated concomitantly with standard therapy, reduces significantly the risk of worsening heart failure events and cardiovascular events, and improves symptoms in patients with heart failure and reduced ejection fraction according to this new work presented during last Sunday’s scientific sessions at the European Society of Cardiology (ESC) Congress 2019.
Read more HERE
4-Do Polymers Play any Role in Drug Eluting Stents
The fact that polymers can degrade after drug release seems interesting, more so when there appears to be evidence that they might cause inflammation (manly eosinophil infiltration) given its unwanted consequences. However, nice theories often get a reality check, and the polymer discussion is no exception.
Read more HERE
5- ESC 2019 | Pure: Body Mass Index Shows Low Correlation with Cardiovascular Events
This population study has found all-cause mortality is lower the lower body mass index (BMI) is, but lower BMI is not necessarily better.
Read more HERE
6-STEMI in Coronary Dissections. When Should We Do It and What Are Its Outcomes?
Generally, coronary artery dissection (SCAD) is not very frequent in young women and presents better evolution with medical treatment. However, it is occasionally associated with ST segment elevation. In this scenario, PCI with stent implantation is quite challenging.
Read more HERE
7-Should Interventional Cardiologists Be Involved in Acute Stroke?
According to this single-site study, published in J Am Coll Cardiol Intv., interventional cardiologists can safely conduct revascularizations in a setting of acute stroke, with high clinical and technical success. Cardiologists are taking on this traditional interventional neurology field simply due to the lack of interventional neurologists, who are thus unable to provide coverage 24/7, 365 days per year.
Read more HERE
8-ESC 2019 | COMPLETE: Definitive Evidence for Infarction with Multivessel Disease
Para los pacientes cursando un infarto con supradesnivel del segmento ST y que además de la arteria culpable presentan otros vasos, la revascularización completa es superior a tratar solamente la arteria culpable en cuanto al end point final combinado de muerte cardiovascular, infarto y revascularización justificada por la isquemia a una media de seguimiento de 3 años. Esta información surge del estudio randomizado Complete, largamente esperado y finalmente presentado en las sesiones científicas del ESC 2019 (y además publicado simultáneamente en NEJM).
Read more HERE
9-DK CRUSH Is Still The Best Option
When it comes to severe unprotected left main distal bifurcation lesions, surgery continues to be the preferred treatment option. However, due to the growing number of patients that cannot receive surgery, left main PCI has significantly advanced, and though the strategy in this scenario remains controversial, double kissing crush stenting (DK CRUSH) was shown superior to provisional stenting (PS) at one-year follow-up (though there is no data beyond this period).
Read more HERE
10-ESC 2019 | ISAR-REACT 5 | Which Is Better in ACS, Prasugrel or Ticagrelor?
The benefit of dual antiplatelet therapy in acute coronary syndromes (ACS) has been proven long ago, and both prasugrel and ticagrelor have offered best results than clopidogrel. However, nowadays, it is unclear which of them is superior in the long term, taking into account the fact that one starts to act before the other.
Read more HERE
Get the latest scientific articles on interventional cardiologySubscribe to our weekly newsletter
We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.
